Page last updated: 2024-11-12

fluocortin butyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fluocortin butyl ester: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15942715
CHEMBL ID2105087
CHEBI ID135728
SCHEMBL ID25218
MeSH IDM0058420

Synonyms (33)

Synonym
fluocortin butyl (usan)
41767-29-7
D04217
butyl 6-alpha-fluoro-11-beta-hydroxy-16-alpha-methyl-3,20-dioxo-1,4-pregnadien-21-oate
sh k 203
pregna-1,4-dien-21-oic acid, 6-fluoro-11-hydroxy-16-methyl-3,20-dioxo-, butyl ester (6alpha,11beta,16alpha)-
varlane
6-alpha-fluor-11-beta-hydroxy-16-alpha-methyl-3,20-dioxo-1,4-pregnadien-21-saure-butylester
fluocortin butyl ester
fluocortin butyl [usan:ban]
butyl 6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-21-oate
einecs 255-543-8
sh-k-203
fluocortin butyl
vaspit
CHEBI:135728
CHEMBL2105087
shk-203
unii-6n7oa9mo7o
6n7oa9mo7o ,
SCHEMBL25218
fluocortin butyl [mi]
fluocortin butyl [mart.]
fluocortin butyl [who-dd]
pregna-1,4-dien-21-oic acid, 6-fluoro-11-hydroxy-16-methyl-3,20-dioxo-, butyl ester (6.alpha.,11.beta.,16.alpha.)-
fluocortin butyl [usan]
DTXSID60194590
fluocortinbutyl
butyl6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-21-oate
Q27265191
butyl 2-[(6s,8s,9s,10r,11s,13s,14s,16r,17s)-6-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoacetate
CS-0026066
HY-106567

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There were few adverse effects."( Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy.
Bierman, CW; Bronsky, E; Connell, JT; Lieberman, PL; Meltzer, EO; Nathan, R; Orgel, HA; Pearlman, DS; Pence, HL; Slavin, RG, 1991
)
0.28

Dosage Studied

ExcerptRelevanceReference
" In subsequent months, one third of the patients was maintained at the dosage of 3 mg/day, one third at a lower dosage of 2 mg/day, and the remaining one third of the patients at a larger dosage of 4 to 8 mg/day."( Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy.
Bierman, CW; Bronsky, E; Connell, JT; Lieberman, PL; Meltzer, EO; Nathan, R; Orgel, HA; Pearlman, DS; Pence, HL; Slavin, RG, 1991
)
0.28
" This was a 4-week study with a 1-week observation (baseline) period and a 3-week period during which the response to three dosage regimens (2 mg per day, 4 mg per day, and 8 mg per day) of FCB and placebo were compared to baseline observations of rhinitis."( Efficacy and tolerance of fluocortin butyl administered twice daily in adult patients with perennial rhinitis.
Hartley, TF; Lieberman, PL; Meltzer, EO; Noyes, JN; Pearlman, DS; Tinkelman, DG, 1985
)
0.27
" Three separate dosage regimens were employed."( Multi-center, double-blind, placebo-controlled trial of fluocortin butyl in perennial rhinitis.
Arbesman, C; Bernstein, IL; Bierman, CW; Bocles, JS; Katz, R; Lieberman, PL; Mattucci, K; Meltzer, EO; Middleton, E; Noyes, J; Pearlman, DS; Pence, HL; Slavin, RG; Spector, SL, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (76.00)18.7374
1990's5 (20.00)18.2507
2000's1 (4.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.49 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (60.71%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (10.71%)4.05%
Observational0 (0.00%)0.25%
Other8 (28.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]